146,525 Shares in Celldex Therapeutics, Inc. $CLDX Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the first quarter, Holdings Channel.com reports. The institutional investor purchased 146,525 shares of the biopharmaceutical company’s stock, valued at approximately $4,648,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Aster Capital Management DIFC Ltd bought a new position in Celldex Therapeutics during the third quarter worth about $26,000. Wilmington Savings Fund Society FSB acquired a new stake in Celldex Therapeutics during the third quarter valued at approximately $42,000. Russell Investments Group Ltd. grew its stake in shares of Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the period. Quantbot Technologies LP bought a new stake in shares of Celldex Therapeutics in the 3rd quarter valued at approximately $63,000. Finally, Kestra Advisory Services LLC acquired a new position in shares of Celldex Therapeutics in the 4th quarter worth approximately $98,000.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on CLDX shares. Wall Street Zen upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Wells Fargo & Company increased their price objective on Celldex Therapeutics from $38.00 to $54.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Monday, April 20th. The Goldman Sachs Group boosted their target price on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a research note on Monday, March 2nd. Finally, UBS Group upped their target price on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.30.

Celldex Therapeutics Price Performance

CLDX stock opened at $37.44 on Tuesday. The company has a 50 day moving average price of $32.13 and a 200 day moving average price of $29.30. Celldex Therapeutics, Inc. has a fifty-two week low of $19.52 and a fifty-two week high of $37.54. The stock has a market capitalization of $2.94 billion, a PE ratio of -8.79 and a beta of 0.95.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.80 million. As a group, equities analysts expect that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.